Get the Stockscreener App
6.71
2.35%
0.12
Calcimedica Inc stock is traded at $6.71, with a volume of 142.52K.
It is up +2.35% in the last 24 hours and up +46.63% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
See More
Previous Close:
$6.59
Open:
$6.74
24h Volume:
142.52K
Relative Volume:
1.86
Market Cap:
$97.19M
Revenue:
-
Net Income/Loss:
$-20.87M
P/E Ratio:
-4.2138
EPS:
-1.5924
Net Cash Flow:
$-21.21M
1W Performance:
+8.27%
1M Performance:
+46.63%
6M Performance:
+326.90%
1Y Performance:
+105.02%
1-Day Range:
$6.0601
$7.20
1-Week Range:
$5.55
$7.20
52-Week Range:
$1.42
$7.20
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
6.745 | 94.96M | 0 | -20.87M | -21.21M | -1.5924 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.77 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.65 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.37 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.57 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.51 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Calcimedica Inc Stock (CALC) Latest News
CalciMedica (NASDAQ:CALC) Trading Down 2.1% – Time to Sell? - Defense World
CalciMedica (NASDAQ:CALC) Trading Down 2.1%Time to Sell? - MarketBeat
Can CalciMedica Inc. stock rebound after recent weaknessInstitutional Buying Trends & Use Time as Your Investing Ally - bollywoodhelpline.com
CalciMedica Hits New 52-week HighBetting On KOURAGE? - RTTNews
New Highs: Will CalciMedica Inc stock reach Wall Street targetsShort Setup & Free Weekly Chart Analysis and Trade Guides - moha.gov.vn
Ideas Watch: Is CalciMedica Inc. stock a top momentum playPortfolio Risk Report & High Accuracy Trade Signal Alerts - moha.gov.vn
CalciMedica Earnings Notes - Trefis
Is CalciMedica Inc. stock a top pick in earnings seasonWeekly Loss Report & Stock Portfolio Risk Management - DonanımHaber
How CalciMedica Inc. stock compares to industry benchmarksWeekly Stock Recap & Capital Efficiency Focused Strategies - DonanımHaber
How CalciMedica Inc. stock reacts to global recession fearsSwing Trade & Stepwise Entry and Exit Trade Signals - DonanımHaber
How CalciMedica Inc. stock performs in rate cut cyclesJuly 2025 Summary & Advanced Technical Signal Analysis - DonanımHaber
Financial Contrast: CalciMedica (NASDAQ:CALC) and GRI Bio (NASDAQ:GRI) - Defense World
Stonepine Capital Management LLC Has $136,000 Stock Position in CalciMedica Inc. $CALC - MarketBeat
Why retail investors favor CalciMedica Inc. stockJuly 2025 Closing Moves & Weekly Top Gainers Alerts - Newser
CalciMedica (CALC) Stock Analysis Report | Financials & Insights - Benzinga
Oppenheimer reiterates Outperform rating on CalciMedica stock ahead of key trial - Investing.com Australia
Oppenheimer reiterates Outperform rating on CalciMedica stock ahead of key trial By Investing.com - Investing.com South Africa
CalciMedica announces presentation of data from Preclinical Study of Auxora - MSN
Is CalciMedica Inc. stock a smart buy before Fed meetingQuarterly Trade Summary & Capital Efficiency Focused Ideas - newser.com
From Calcium Channels To Cash Runway: Why CalciMedica Is A Stock To Watch - RTTNews
Will CalciMedica Inc. stock pay special dividendsJuly 2025 Action & Target Return Focused Picks - newser.com
What MACD and RSI say about CalciMedica Inc.July 2025 Outlook & Consistent Profit Alerts - newser.com
Technical signs of recovery in CalciMedica Inc.2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
Is CalciMedica Inc. still worth holding after the dipTrade Entry Report & AI Forecasted Entry/Exit Points - newser.com
Is CalciMedica Inc. stock near bottom after declinePortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
What recovery options are there for CalciMedica Inc.2025 Year in Review & Fast Moving Stock Trade Plans - newser.com
Is CalciMedica Inc. stock reversal real or fakeGap Down & Weekly Return Optimization Plans - newser.com
Tools to monitor CalciMedica Inc. recovery probability2025 Market Trends & Expert Curated Trade Ideas - newser.com
Best data tools to analyze CalciMedica Inc. stockTrade Performance Summary & AI Powered Buy/Sell Recommendations - newser.com
How to build a custom watchlist for CalciMedica Inc.July 2025 Catalysts & Smart Swing Trading Alerts - newser.com
Analyzing CalciMedica Inc. with risk reward ratio chartsJuly 2025 Retail & Free Reliable Trade Execution Plans - newser.com
Why CalciMedica Inc. stock remains on buy listsJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Should I hold or sell CalciMedica Inc. stock in 2025Market Rally & Scalable Portfolio Growth Methods - newser.com
Can CalciMedica Inc. recover in the next quarterWeekly Profit Recap & Reliable Volume Spike Alerts - newser.com
Will CalciMedica Inc. stock return to pre crisis levelsJuly 2025 Update & Growth Focused Entry Reports - Fundação Cultural do Pará
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Calcimedica Inc Stock (CALC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 15 '25 |
Buy |
2.68 |
3,400 |
9,105 |
81,650 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 12 '25 |
Buy |
3.12 |
5,000 |
15,600 |
78,250 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 09 '25 |
Buy |
3.15 |
2,343 |
7,378 |
73,250 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 28 '25 |
Buy |
2.86 |
9,200 |
26,340 |
70,107 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 29 '25 |
Buy |
2.74 |
800 |
2,192 |
70,907 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 21 '25 |
Buy |
2.79 |
3,508 |
9,797 |
60,907 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 20 '25 |
Option Exercise |
1.53 |
15,000 |
22,950 |
179,706 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 20 '25 |
Buy |
2.72 |
2,000 |
5,440 |
57,399 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 19 '25 |
Buy |
2.79 |
1,000 |
2,790 |
55,399 |
| Hebbar Sudarshan | Chief Medical Officer |
Aug 19 '25 |
Buy |
2.82 |
9,563 |
26,962 |
61,539 |
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):